Analysis of epithelial-mesenchymal transition markers in the histogenesis of hepatic progenitor cell in HBV-related liver diseases

Wei Xu1†, Nong-Rong Wang2,3†, Hua-Feng Wang4†, Qiong Feng5,6†, Jun Deng7†, Zhi-Qiang Gong6, Jian Sun2, Xiao-Liang Lou2, Xue-Feng Yu2, Lv Zhou8, Jin-Ping Hu9, Xiao-Feng Huang8, Xiao-Qing Qi8, Yan-Juan Deng8, Rui Gong2, Yan Guo4, Meng-Meng Wang2, Jia-Cheng Xiao4,9 and Huan Deng2,6,8,10∗

Abstract

**Background:** The origin and heterogeneity of hepatic progenitor cells (HPCs) remain unclear. This study aimed to investigate the involvement of epithelial-mesenchymal transition (EMT) in the histogenesis of HPCs.

**Methods:** Surgical liver specimens from patients with HBV-related hepatitis and cirrhosis were investigated with double immunofluorescence labeling to detect antigens associated with HPCs and EMT. Ductular reactions were subjected to quantitative reverse transcription PCR following isolation by laser capture microdissection. Electron microscopic examination was performed to find an ultrastructural evidence of EMT.

**Results:** The number of EpCAM-positive HPCs was proportional to the disease severity. The S100A4 expression of HPCs was firstly observed in mild hepatitis and increased significantly in moderate hepatitis, but decreased in severe hepatitis and cirrhosis. The levels of MMP-2, Twist, and Snail increased in direct proportion to the number of HPCs. Some hepatocytes adjacent to portal tracts in cirrhosis showed positivity for MMP-2. Although CK7 and E-cadherin levels decreased in mild and moderate hepatitis, HPCs re-expressed both of them in severe hepatitis and cirrhosis. However, HPCs expressed neither vimentin nor αSMA. The relative mRNA expression levels of EpCAM and EMT-associated markers supported immunohistochemical results. Electron microscopic examination demonstrated the existence of intercellular junctions among HPCs, cholangiocytes, and intermediate hepatocyte-like cells.

**Conclusion:** We provided preliminary evidence for the involvement of EMT in the histogenesis of HPCs from cholangiocytes in HBV-related liver diseases. HPCs may re-transdifferentiate into hepatocytes, and the differentiation direction depends, at least in part, on interactions between HPCs and the surrounding microenvironment, especially the non-resolving inflammation caused by HBV infection.

**Keywords:** Hepatic progenitor cell, Epithelial-mesenchymal transition, HBV, Cholangiocyte, Histogenesis

* Correspondence: beandeng@ncu.edu.cn
† Equal contributors
2 Molecular Medicine and Genetics Center, The Fourth Affiliated Hospital of Nanchang University, Nanchang, China
6 Renmin Institute of Forensic Medicine in Jiangxi, Nanchang, China
Full list of author information is available at the end of the article

© The Author(s), 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

It is well known that terminal stage liver diseases can be treated by liver transplantation with relatively good five-year survival. However, limited donor organs and rejection reactions restrict its usage. Thus, it is necessary to establish a novel strategy. Hepatic progenitor cells (HPCs)-based therapy is considered to be a promising replacement for liver transplantation because HPCs are capable of differentiating into both hepatocyte and biliary lineage [1, 2]. However, this therapeutic strategy cannot be fully exploited until the mechanisms underlying the histogenesis of HPCs are clearly elucidated. It is traditionally assumed that HPCs originate in the smallest ramifications of the bile ducts or in locations outside the liver, such as bone marrow (BM) [3–5]. However, liver stem cells have never been observed in the adult liver. Meanwhile, the restricted potential to differentiate into hepatocytes and cholangiocytes also qualifies HPCs as true stem cells [6]. Recent studies suggested that EMT is involved in the pathogenesis of liver cirrhosis, a common endpoint of most chronic liver diseases. There is now convincing evidence that TGF-β1 can induce both cultured hepatocytes and cholangiocytes to undergo EMT [7–9]. Notably, some cells undergoing EMT/MET (mesenchymal-epithelial transition) can simultaneously express epithelial/mesenchymal markers and HPCs markers [10]. Furthermore, they can repair injured liver in rodent models [11], raising the exciting possibility that HPCs may represent a subpopulation of cells undergoing EMT/MET [12]. However, most available evidence supporting this hypothesis is indirect and obtained from rodent models or in vitro studies.

The EMT is a dynamic process that cannot be followed serially in humans because of technical limitations. In this study, we examined specimens from patients with benign HBV-related diseases, including hepatitis and cirrhosis. We used double immunofluorescence staining and RT-qPCR (quantitative reverse transcription PCR) to detect characteristic markers that are associated with HPCs, EMT, and epithelial/mesenchymal cells. In this study, EpCAM was used for identification of HPCs, because several studies indicated that EpCAM is capable of relative higher specificity than other HPCs markers such as CD133, CK19, and OV-6 [13–15]. S100A4, the human homolog of murine fibroblast-specific protein 1 (FSP1), has been demonstrated to be a key marker of early fibroblast lineage development and EMT [16, 17]. Consequently, loss of cytokeratin (CK) and adherens junction components such as E-cadherin promotes the detachment of transitioning cells from primary sites [18, 19]. At later stages, EMT is accompanied by an increase in motility and matrix invasion, which is consistent with elevated levels of vimentin and matrix metalloproteinases (MMPs) [19]. EMT-derived fibroblast cells can express α-smooth muscle actin (αSMA) [20]. Meanwhile, several nuclear transcription factors contribute to the EMT cascade. Twist, a known helix-loop-helix transcription factor, can directly affect its down-stream element Snail to suppress the expression of E-cadherin [21–23].

Methods

Patients and clinical data

Sixty patients (42 men and 18 women) with HBV-related diseases were enrolled. Serum HBV DNA should be ≥2.5 pg/mL and last at least 3 months. Fifteen samples obtained from liver donors served as control. A part of each sample was snap-frozen and stored at −80 °C until being used for laser capture microdissection (LCM). Clinical data were recorded (Table 1). All patients gave written informed consent to participate in the study in accordance with the Helsinki Declaration, and this study was approved by the Regional Ethics Committee (Medical Ethics Committee of The Fourth Affiliated Hospital of Nanchang University and Ruijin Hospital, School of Medicine, Shanghai Jiaotong University).

Histopathological examination

The histopathological evaluation of all sections was performed by two independent researchers (JH Mei and YQ Xiao) who were blinded regarding patient details. The method proposed by Bedossa et al. was served as grading standard [24] (Table 2).

Double immunofluorescence labeling and morphometric determinations

The formalin fixed and paraffin embedded tissues were cut at 2- to 5-μm and retrieved in citrate buffer (pH 6.0) at 95 °C for 15 min. These slides were then blocked with 20% BSA before the incubation with a cocktail for EpCAM and one of the EMT-associated markers at 4 °C overnight (Table 3). Two different antibodies for EpCAM were employed in this study to avoid cross-reactions (Table 3). Serial sections from three breast ductal carcinoma samples served as the positive control to compare the sensitivity and specificity of the two different EpCAM antibodies according to manufacturer’s instruments. Two independent pathologists, who were blinded regarding staining details, evaluated and recorded the extent and intensity of sections respectively by using the following arbitrary scale: 0: ≤ 25%, no staining; 1: 26–50%, weak staining; 2: 51–75%, moderate staining; 3: 76–100%, strong staining. Statistical analysis based on the accumulated scores suggested that there were no significant differences between the two antibodies (p < 0.01). FITC or TRITC-conjugated secondary antibodies (Jackson Immunoresearch, USA) were incubated with the pretreated slides at room temperature for 60 min. The dilutions were 1:100 and 1:150, respectively.
| Case | Sex | Age (years) | Disease        | AST (IU/L) | ALT (IU/L) | Albumin (g/L) | Total bilirubin (μmol/L) | Platelet (×10^9/L) | Serum AFP (n/g/mL) |
|------|-----|-------------|----------------|------------|------------|---------------|--------------------------|-------------------|-----------------|
| 1    | M   | 28          | Hepatitis (Mild)| 25         | 20         | 35            | 15.7                     | 62                | 5.8             |
| 2    | M   | 49          | Hepatitis (Mild)| 17         | 22         | 38            | 19.3                     | 321               | 5.2             |
| 3    | F   | 27          | Hepatitis (Mild)| 18         | 31         | 30            | 31.9                     | 158               | 10              |
| 4    | F   | 58          | Hepatitis (Mild)| 21         | 11         | 41            | 19.2                     | 71                | 3.39            |
| 5    | M   | 56          | Hepatitis (Mild)| 21         | 28         | 41            | 12.4                     | 240               | 9.01            |
| 6    | M   | 50          | Hepatitis (Mild)| 33         | 25         | 59            | 28.5                     | 257               | 5.2             |
| 7    | M   | 39          | Hepatitis (Mild)| 18         | 15         | 24            | 12                       | 158               | 3.2             |
| 8    | M   | 24          | Hepatitis (Mild)| 21         | 19         | 36            | 10.5                     | 182               | 6.82            |
| 9    | M   | 28          | Hepatitis (Mild)| 39         | 50         | 41            | 22.9                     | 234               | 4.45            |
| 10   | M   | 32          | Hepatitis (Mild)| 25         | 26         | 39            | 12.3                     | 120               | 5.3             |
| 11   | M   | 36          | Hepatitis (Mild)| 14         | 16         | 41            | 19.3                     | 178               | 4.3             |
| 12   | M   | 28          | Hepatitis (Mild)| 24         | 18         | 28            | 5.6                      | 205               | 5.25            |
| 13   | M   | 22          | Hepatitis (Mild)| 30         | 24         | 39            | 23.1                     | 124               | 2.8             |
| 14   | M   | 42          | Hepatitis (Mild)| 27         | 31         | 29            | 22.2                     | 94                | 9.4             |
| 15   | F   | 47          | Hepatitis (Mild)| 22         | 23         | 44            | 16                       | 322               | 2.6             |
| 16   | F   | 31          | Hepatitis (Mild)| 43         | 41         | 28            | 21.3                     | 167               | 10.2            |
| 17   | F   | 38          | Hepatitis (Moderate)| 30   | 29         | 41            | 22.4                     | 203               | 4.2             |
| 18   | M   | 39          | Hepatitis (Moderate)| 18   | 17         | 30            | 21.4                     | 205               | 6.2             |
| 19   | M   | 41          | Hepatitis (Moderate)| 25   | 23         | 35            | 29                       | 231               | 2.9             |
| 20   | M   | 32          | Hepatitis (Moderate)| 31   | 29         | 27            | 17.4                     | 160               | 1.84            |
| 21   | M   | 28          | Hepatitis (Moderate)| 40   | 47         | 42            | 13.4                     | 205               | 9.2             |
| 22   | M   | 57          | Hepatitis (Moderate)| 22   | 19         | 42            | 21.8                     | 265               | 4.28            |
| 23   | F   | 41          | Hepatitis (Moderate)| 25   | 30         | 37            | 10.8                     | 46                | 4.38            |
| 24   | F   | 57          | Hepatitis (Moderate)| 21   | 12         | 19            | 31.3                     | 254               | 3.21            |
| 25   | M   | 39          | Hepatitis (Moderate)| 28   | 36         | 32            | 14.8                     | 269               | 3.42            |
| 26   | M   | 24          | Hepatitis (Moderate)| 39   | 21         | 57            | 19.9                     | 189               | 3.02            |
| 27   | M   | 60          | Hepatitis (Moderate)| 21   | 14         | 30            | 12.4                     | 94                | 3.59            |
| 28   | F   | 25          | Hepatitis (Moderate)| 32   | 21         | 51            | 20                       | 109               | 2.5             |
| 29   | F   | 39          | Hepatitis (Moderate)| 23   | 26         | 41            | 21.3                     | 206               | 11.7            |
| 30   | M   | 42          | Hepatitis (Moderate)| 48   | 35         | 44            | 25.1                     | 207               | 8.2             |
| 31   | F   | 39          | Hepatitis (Severe)| 54   | 92         | 26            | 35                       | 307               | 10.6            |
| 32   | M   | 52          | Hepatitis (Severe)| 35   | 37         | 18            | 15                       | 184               | 1.23            |
| 33   | M   | 36          | Hepatitis (Severe)| 23   | 71         | 39            | 23.1                     | 159               | 9.08            |
| 34   | M   | 21          | Hepatitis (Severe)| 35   | 49         | 25            | 38.1                     | 93                | 3.57            |
| 35   | M   | 31          | Hepatitis (Severe)| 28   | 58         | 62            | 29.5                     | 222               | 4.9             |
| 36   | M   | 39          | Hepatitis (Severe)| 23   | 31         | 31            | 16.6                     | 81                | 2.2             |
| 37   | M   | 26          | Hepatitis (Severe)| 18   | 24         | 50            | 20.7                     | 152               | 8.1             |
| 38   | F   | 27          | Hepatitis (Severe)| 29   | 42         | 41            | 29.1                     | 121               | 2.7             |
| 39   | M   | 40          | Hepatitis (Severe)| 7    | 15         | 25            | 15.2                     | 106               | 3.9             |
| 40   | M   | 47          | Hepatitis (Severe)| 37   | 27         | 31            | 8.2                      | 83                | 4.6             |
| 41   | M   | 33          | Hepatitis (Severe)| 24   | 62         | 28            | 43.2                     | 119               | 3.12            |
| 42   | M   | 51          | Hepatitis (Severe)| 16   | 36         | 32            | 24.3                     | 132               | 7.9             |
| 43   | M   | 32          | Hepatitis (Severe)| 41   | 61         | 18            | 16.8                     | 182               | 10              |
| 44   | F   | 41          | Hepatitis (Severe)| 66   | 34         | 30            | 38.7                     | 204               | 4.33            |
Finally, the slides were washed with PBS for three times and mounted with anti-fade medium (Vector, USA). A Nikon 80i microscope with the Intensilight fluorescence set and DS-Ri2 camera (Nikon, Japan) was used to perform the image analysis.

HPCs were considered to be small to medium EpCAM-positive cells localizing within ductular reactions (DRs). Counting of positive cells was conducted on sections with an immunofluorescence microscope. The corresponding number of non-overlapping fields in the section was counted using the 40× objective. The average number of positive cells in each square centimeter was calculated for each specimen.

**LCM and RT-qPCR**
Frozen sections were placed onto PET-membrane slides (Leica Microdissect, Herborn, Germany) and briefly stained with hematoxylin and eosin (H&E). DRs were dissected using LCM with a Leica SVS LMD System (Leica Microsystems, Wetzlar, Germany). A sufficient number of cells were obtained from 5 to 10 tissue sections. RNA was isolated using an RNeasy Micro Kit (Qiagen, Hilden, Germany) and then evaluated by the Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) as in a previous study [13]. RT-qPCR was performed with a Select cDNA Synthesis Kit (Bio-Rad, California, USA). Relative mRNA levels of targeted genes were measured by RT-qPCR during 40 cycles and expressed as ΔCt values when compared to GAPDH (primer sequences see Table 4) [25].

**Transmission electron microscopic (EM) examination**
All tissues were fixed in 4% glutaraldehyde in 0.1 m phosphate buffer pH 7.3 and embedded in Epon 812. Following double staining with uranyl acetate and lead nitrate, tissues were cut into thin sections and observed under a transmission electron microscope (H-9520, Hitachi, Japan).

### Table 1
Clinical, biochemical and histopathological characteristics of patients with HBV associated diseases (Continued)

| No. | Gender | Age | Disease | ALT | Total bilirubin | Direct bilirubin |
|-----|--------|-----|---------|-----|----------------|-----------------|
| 45  | M      | 25  | Hepatitis (Severe) | 20  | 15             | 50              |
| 46  | F      | 51  | non-HCC cirrhosis  | 12  | 41             | 48              |
| 47  | M      | 47  | non-HCC cirrhosis  | 31  | 21             | 42              |
| 48  | M      | 38  | non-HCC cirrhosis  | 27  | 33             | 26              |
| 49  | M      | 40  | non-HCC cirrhosis  | 47  | 36             | 40              |
| 50  | F      | 41  | non-HCC cirrhosis  | 30  | 14             | 28              |
| 51  | M      | 55  | non-HCC cirrhosis  | 38  | 10             | 28              |
| 52  | F      | 60  | non-HCC cirrhosis  | 20  | 51             | 32              |
| 53  | M      | 49  | non-HCC cirrhosis  | 44  | 27             | 35              |
| 54  | M      | 54  | non-HCC cirrhosis  | 20  | 42             | 21              |
| 55  | M      | 59  | non-HCC cirrhosis  | 25  | 26             | 46              |
| 56  | M      | 48  | non-HCC cirrhosis  | 19  | 15             | 39              |
| 57  | F      | 32  | non-HCC cirrhosis  | 307 | 342            | 49              |
| 58  | M      | 56  | non-HCC cirrhosis  | 22  | 19             | 26              |
| 59  | F      | 53  | non-HCC cirrhosis  | 31  | 26             | 24              |
| 60  | F      | 47  | non-HCC cirrhosis  | 20  | 25             | 51              |

### Table 2
Histological activity of liver biopsy of chronic hepatitis B

| Histological Activity | Histological Feature |
|-----------------------|----------------------|
| Mild (A1)             | PMN = 0 LN = 1       |
|                       | PMN = 1 LN = 0, 1    |
| Moderate (A2)         | PMN = 0 LN = 2       |
|                       | PMN = 1 LN = 2       |
|                       | PMN = 2 LN = 0, 1    |
| Severe (A3)           | PMN = 2 LN = 2       |
|                       | PMN = 3 LN = 0, 1, 2 |

PMN, piecemeal necrosis; 0, none; 1, mild; 2, moderate; 3, severe; LN, lobular necrosis; 0, no or mild; 1, moderate; 2, severe

### Table 3
Summary of primary antibody used for immunohistochemistry

| Antibody | Isotype | Supplier | Dilution |
|----------|---------|----------|----------|
| EpCAM    | lgG1(rabbit) | Epitomics | 1:300    |
| EpCAM    | lgG1(mouse)  | abcam    | 1:100    |
| Cytokeratin 7 | lgG1(mouse) | DAKO    | 1:100    |
| E-Cadherin | lgG1(mouse) | DAKO    | 1:50     |
| S100A4    | lgG(rabbit)  | abcam    | 1:50     |
| MMP-2     | lgG(rabbit)  | abcam    | 1:250    |
| Twist     | lgG1(mouse)  | abcam    | 1:150    |
| Snail     | lgG(rabbit)  | abcam    | 1:100    |
| Vimentin  | lgG1(mouse)  | DAKO    | 1:100    |
| α-SMA     | lgG2a(mouse) | DAKO    | 1:100    |

Xu et al. Diagnostic Pathology (2016) 11:136
citrate, the sections were examined using a Philips CM120 transmission EM.

Statistical analysis
Continuous normally distributed variables are represented as mean ± SD. The inflammatory grade was summarized by the median. ANOVA was used to evaluate the difference among the comparative mRNA expression of each gene in normal, hepatitis and cirrhosis specimens. The LSD-t test was applied for post-hoc comparisons. P<0.05 was considered statistically significant. Data analyses were carried out using SPSS version 13.0 for Windows (SPSS, Inc., Chicago, USA).

Results
Expression of EMT markers in HBV-related liver diseases
In normal liver, DRs were absent and cholangiocytes in intrahepatic bile duct showed positivity for CK7 and E-cadherin (Figs. 1a, and 2a, f). They did not express EpCAM or EMT-associated markers (Figs. 1f, k and 2k, 2p).

Although a definite phenotypic marker has not yet been developed, S100A4 has been described as one of the earliest makers and activators of EMT [17]. In sections from patients with mild and moderate inflammation, some but not all S100A4-positive cells expressed the HPC marker EpCAM (n = 1.19 ± 0.68 per cm² and n = 3.09 ± 0.52 per cm², respectively) (Fig. 1g, h). Noteworthy, only a few of HPCs in sections of severe

| Table 4 | The sequences of primers used in qRT-PCR |
|---------|----------------------------------------|
| Gene    | Sense                                  | Antisense                                      | Product (bp) |
| EpCAM   | CTGGACTGGAATGCTGAG                     | CGAAGATGACGTAGAGGAT                           | 178          |
| S100A4  | GATGAGCACTTGAGAGCAAC                   | CTGGGCTGCTATCTGGAAAG                          | 123          |
| MMP-2   | CGTGCCGCTATCAAGG                      | CTGCTGCGCATGCAGAAG                            | 169          |
| Twist   | GAATGACCGCTGTGGAAGAA                   | CGATGGAAGGATGCTGGAGGAC                       | 199          |
| Snail   | ACTACTGTCGGAGGTGAGAAGT                 | CTGCAACTGGGATGCTGAT                          | 123          |
| CK7     | TTGTTGCTGCTGAGAAG                     | CTGTTGCGTTGAGAAG                             | 117          |
| E-cadherin | CGAGAGCTACACGTCAGG                  | GTGCGAGGGGAAATAGGGGTC                       | 238          |
| Vimentin | GACGCGCTACACCCGGAGGT                  | CTGCTGAGGGATGCTGAT                          | 109          |
| αSMA    | GAGAGTGGATTGTGAGG                       | GAAGGTGAGGGAGTGAG                            | 230          |

Fig. 1 The expressions of S100A4 and MMP-2 in HPCs. a, f, k In sections from normal liver, parenchymal cells expressed neither S100A4 nor MMP-2 (original magnification × 200). b, g, l Some HPCs in mild hepatitis showed immunopositivity for EpCAM, rather than MMP-2, (original magnification × 200, inserts, original magnification × 400). c, h, m Majority of HPCs in moderate hepatitis expressed strong-diffuse cytoplasmic positivity for S100A4 and MMP-2 (original magnification × 200, inserts, original magnification × 400). d, i, n The expression level of S100A4 decreased significantly in HPCs from severe hepatitis. But HPCs expressed a high level of MMP-2 (original magnification × 200, inserts, original magnification × 400). e, j, o HPCs in cirrhosis sections showed negativity for S100A4. Both HPCs and intermediate hepatocytes (arrow) adjacent to portal tracts expressed MMP-2 (original magnification × 200).
inflammation and cirrhosis expressed S100A4 (n = 1.02 ± 0.44 per cm² and n = 0.26 ± 0.17 per cm²) (Fig. 1i, j).

MMPs comprise a large family that regulates essential steps of embryogenesis and wound healing. Our results showed that HPCs and hepatocytes in sections of mild hepatitis were negative for MMP-2 (Fig. 1l). In moderate and severe hepatitis, a portion of HPCs expressed MMP-2 (n = 2.45 ± 0.98 per cm² and n = 2.45 ± 0.98 per cm², respectively) (Fig. 1m, n). Some intermediate hepatocyte-like cells (IHLCs) adjacent to portal tracts from patients with cirrhosis showed immunopositivity for MMP-2 rather than EpCAM (Fig. 1o).

The proteomic features of EMT also include the loss of epithelial markers. Although almost all of HPCs within DRs of mild hepatitis co-expressed CK7 and E-cadherin (n = 1.77 ± 0.83 per cm² and n = 1.42 ± 0.76 per cm², respectively), a few of HPCs displayed neither of them (Fig. 2b, g). The number of CK7- or E-cadherin-positive HPCs decreased significantly in moderate hepatitis (n = 0.65 ± 0.33 per cm² and n = 0.78 ± 0.45 per cm², P < 0.05) (Fig. 2c, h). Noteworthy, HPCs expressed elevated levels of CK7 and E-cadherin in severe hepatitis and cirrhosis as compared to mild hepatitis (n = 2.11 ± 0.64 per cm², 3.08 ± 0.52 per cm², and n = 1.87 ± 0.56 per cm², 3.18 ± 0.49 per cm², P < 0.05) (Fig. 2d, e, i, and j).

Repression of E-cadherin by transcriptional regulators such as Twist and Snail serves as a key event during EMT [26]. Nuclear positivity for Twist or Snail in HPCs was firstly detected in sections of mild hepatitis (n = 1.62 ± 0.49 per cm² and n = 1.70 ± 0.52 per cm², respectively) (Fig. 2l, q), and the number of Twist- or Snail-positive HPCs was proportional to the severity of HBV-related disease (n = 2.65 ± 0.83, 3.79 ± 0.33, 4.91 ± 0.39 per cm² and n = 2.41 ± 0.45, 3.66 ± 0.81, 4.78 ± 0.53 per cm², respectively, P < 0.05).

The expression of αSMA and vimentin during EMT indicates the transdifferentiation from epithelial cells into mature mesenchymal cells such as myofibroblasts. In sections of normal, hepatitis, and cirrhotic liver, HPCs, and parenchymal cells did not express αSMA or vimentin (data not show).

Comparison of mRNA expression of EMT-associated markers

We employed LCM to collect DRs (Fig. 3). Total RNA extracted from the microdissected samples was 37–102 ng. Consistent with the double immunofluorescence staining
results, RT-qPCR showed that normal bile ducts did not show aberrant expression of EpCAM nor EMT-associated markers. The elevated mRNA levels of EpCAM, S100A4, Twist, or Snail were firstly confirmed in mild hepatitis and showed a positive relationship with inflammation severity. S100A4 mRNA expression in severe inflammation liver specimens was significantly higher than that in cirrhotic liver \( (P < 0.001) \) (Fig. 4). The expression of MMP-2 increased significantly in moderate, severe hepatitis and cirrhotic liver \( (P < 0.001) \). DRs in HBV-related diseases did not express vimentin and αSMA. The reduction in mRNA expression of the epithelial markers CK7 and E-cadherin was detected in mild and moderate hepatitis \( (P < 0.001) \). However, their expression levels increased and paralleled the severity of diseases in severe hepatitis and cirrhosis \( (P < 0.001) \) (Fig. 4).

**Ultrastructural findings**

HPCs, characterized by their oval shape, small size (7 to 15 μm in diameter) and scanty electron-dense cytoplasm,
existed in all specimens of HBV-related diseases (Fig. 5a). Intercellular junctions were noted between HPCs and some IHLCs. The latter is characterized by abundant cytoplasm and mitochondria, fewer tonofilament bundles compared with HPCs (Fig. 5a, b). The cellular junctions were also observed between HPCs, cholangiocytes, and intermediate hepatocyte-like cells, suggesting a transdifferentiation from mature cholangiocyte to immature hepatocyte (Fig. 5a). Additionally, HPCs at the portal tract/hepatocyte interface contained a greater number of tonofilament bundles than HPCs in the periportal tract, suggesting the intriguing possibility of epithelial phenotype reacquisition (Fig. 5b).

**Discussion**

Despite recent advances in pathophysiology, the histogenesis and heterogeneity of HPCs in humans are matters of debate. In this study, we combined data from immunophenotypic and mRNA studies with ultrastructural examination to provide preliminary evidence for the involvement of EMT in the histogenesis of HPCs in HBV-related liver diseases.

![Fig. 4](image1.png) mRNA expression levels of HPCs after tissue picking by laser capture microdissection. The expression levels of EpCAM, S100A4, MMP-2, CK7, E-cadherin, Twist, and Snail were detected by RT-qPCR. * mild hepatitis versus normal control, \textit{P} < 0.05; ++ moderate hepatitis versus mild hepatitis, \textit{p} < 0.05; § severe hepatitis versus moderate hepatitis, \textit{P} < 0.05; ▲ cirrhosis versus severe hepatitis, \textit{P} < 0.05; ** cirrhosis versus severe hepatitis, \textit{P} > 0.05

![Fig. 5](image2.png) EM examination was performed to find ultrastructural evidence for the transition. a Three HPCs identified by EM. An IHLC with more cytoplasm and mitochondria than HPCs was in close association with HPCs. b There were intercellular junctions among HPCs, cholangiocytes, and intermediate hepatocyte (arrow). Tonofilament bundles in cytoplasm of HPCs indicated the reacquisition of epithelial characteristic (arrowhead)
S100A4, which modifies cell motility and growth through interactions with the cytoskeleton and the C-terminus of p53, has been proposed as an early marker of EMT [17]. Co-expression of EpCAM and S100A4 provided clear evidence that although these HPCs have an epithelial phenotype, they are actively engaged in EMT. HPCs also expressed another important EMT marker MMP-2, which possesses the ability to degrade basement membrane and increases cell motility [27]. The activity of MMPs can alter the expression of E-cadherin and vimentin and promote the EMT process [28]. High levels of MMP-2 may promote the dispatch of HPCs from DRs.

A hallmark of EMT is the aberrant expression of E-cadherin (encoded by CDH1), which is always linked to the tumorigenesis of many epithelial cancers [29]. E-cadherin is a key factor of cell-cell adhesion junctions in the maintenance of cell polarity and structure. Recent studies uncovered its critical roles in proliferation, differentiation, and carcinogenesis. Analogous to cholangitis, the loss of E-cadherin in the liver contributes to the periportal inflammation and later periductal fibrosis [30]. A study making use of a transgenic mouse model where the expression of cre was directed by the albumin enhancer/promoter (termed Alb-cre) demonstrated that these lesions arose as a consequence of the loss of E-cadherin in the cholangiocytes [30]. The reexpression of cre in hepatocytes could not attenuate the effects [31, 32]. In this study, the expression of E-cadherin and CK7 in HPCs decreased significantly from mild hepatitis to moderate hepatitis, revealing that these transitioning cells might derive from epithelial cells within DRs and were losing cell-cell contacts. However, the number and ratio of E-cadherin- or CK7-positive HPCs increased in sections of severe hepatitis and cirrhosis, suggesting that the transitioning cells might reverse the cascade and reacquire epithelial characteristics.

Twist is a core element during EMT process [22]. The overexpression or promoter methylation of Twist is always associated, in a statistically significant manner, with the tumor aggressiveness [33–35]. Activated Twist binds to the promoter region of E-cadherin and transcriptionally downregulates E-cadherin expression [36]. Together with the polycomb protein Bmi1, Twist contributes to the stemness of cells, which is one of the most important features of HPCs [22].

Snail is a zinc-finger transcription factor, which can induce EMT by repression of E-cadherin [23]. TGF-β promotes EMT by up-regulating Snail expression via a Smad-dependent pathway. Snail forms a transcriptional repressor complex with SMAD3/4. The complex then targets the adjacent E-boxes and Smad-binding elements in genes encoding junction proteins such as E-cadherin, CAR and occluding [37].

In all hepatitis and cirrhotic sections, the majority of HPCs within DRs or bile ducts expressed high levels of Twist or Snail, which are proportional to the severity of HBV-related diseases. RT-qPCR further validated these findings, indicating that Twist and Snail were involved in the EMT process of HPCs via the repression of E-cadherin in HBV-related diseases.

We tried to obtain further evidence for the transdifferentiation from HPCs into mature mesenchymal cells by using antibodies for αSMA and vimentin. However, neither cholangiocytes nor hepatocytes expressed αSMA or vimentin in this study. We considered two possibilities for this situation. First, αSMA- or vimentin-positive HPCs may detach from DRs because of an increase in motility and matrix invasion [38]. Hence, these transitioning cells at an advanced stage of EMT do not express EpCAM and detach from DRs. Second, as reversibility is an important feature of EMT, it is tempting to speculate that these transitioning cells may retransdifferentiate into parenchymal cells through MET under certain conditions.

Although we did not obtain substantial results about whether hepatocytes could transdifferentiate into HPCs through EMT, some periportal intermediate hepatocytes in sections from cirrhotic livers showed immunopositivity for MMP-2. We postulated an intriguing possibility that, at least in HBV-related liver diseases, intermediate hepatocytes may represent daughter cells of HPCs rather than a cellular origin of HPCs. Ultrastructural evidence that intercellular junctions existed between HPCs and intermediate hepatocytes further supported this hypothesis. Consistent with our findings, a recent study based on an established rodent model provided convincing evidence for challenging the concept that hepatocytes can acquire a mesenchymal phenotype in vivo via EMT [39]. In contrast, previous studies demonstrated that hepatocytes may also be capable of undergoing EMT in vitro [40, 41]. Furthermore, an elaborate study indicated that the Hippo signal pathway can direct hepatocytes to transdifferentiate into HPC-like cells and finally mimic an atypical ductular reaction [42]. We believe that different microenvironments may result in different outcomes. Most recently, an elaborate study provided supporting evidence [43]. Foetal HPCs can form hepatic cysts characterized by Albumin-positive/CK19-negative in vitro. However, if foetal HPCs are pre-cultured on gelatin-coated dishes, they are capable of forming cholangiocytic cysts expressing Albumin-negative/CK19-positive, similar to that of HPCs [43]. This cholangiocytic cysts formation can be hampered by hepatic maturation factors, such as hepatocyte growth factor (HGF) and oncostatin M (OSM). Of note, the study also indicated that TGF-β antagonist A-8301 plays an important role in the cholangiocytic cysts formation. It seems that this
conclusion is consistent with our hypothesis and observations in vivo. TGF-β derived from portal parenchymal cells or infiltrating immune cells promotes the entrance of cholangiocytes into the EMT cascade and transdifferentiation into hepatocyte-like cells. However, further experiments will be required to gain more insights into the regulatory mechanisms.

Chronic HBV infection may serve as a powerful driver of EMT. The regeneration capacity of mature hepatocytes is overwhelmed during massive or chronic liver infection. Various cytokines released from injured parenchymal cells establish a stable inflammatory infiltrate through the recruitment of leukocytes from blood [44]. T-cells mediate both liver injury and viral clearance in animal models of HBV infection and produce regulatory cytokines such as TGF-β, a powerful driver of EMT [45–47]. Furthermore, T-cells can express integrin, allowing the adhesion to E-cadherin of the epithelium [48]. We speculate that high level of TGF-β induces EMT of DRs at the portal tract. These transitioning cells are capable of transdifferentiation into HPCs and movement towards injured sites, resembling chemotaxis. Since the number of immune cells and parenchymal cells decreases and results in the reduced TGF-β1 level at the lobule boundaries, the transitioning cells/HPCs may reverse EMT cascade and re-transdifferentiate into hepatic lineage to restore parenchyma [12]. The ultrastructural result that tonofilament bundles reoccurred in the cytoplasm of HPCs favors this opinion.

Non-resolving inflammation is established when the recruitment of inflammatory cells outstrips the mechanisms of resolution, including the apoptosis and the migration through lymphatics [49]. Non-resolving inflammation is responsible for abnormally elevated expression of TGF-β1 and the receptor for advanced glycation endproducts (RAGE), which plays an important role in the regulation of HPCs activation [50]. Consequently, most of the HPCs undergo complete EMT and differentiate into mature mesenchymal cells. The repair process is mainly fibrogenic because of the excess production and deposition of extracellular matrix components. The genetic or epigenetic changes may increase the susceptibility of HPCs to the detrimental microenvironment and result in self-renewing cells. Finally, HPCs or their progeny may transform to malignant cells because of the further accumulation of other alterations [50].

Conclusion

Taken together, our study provided preliminary evidence that, at least in HBV-related hepatitis and cirrhosis, EMT is associated with the histogenesis and differentiation of HPCs. Ultrastructural results confirmed the direct interaction between HPCs and intermediate hepatocyte-like cells. The presence of tonofilament bundles in HPCs combined with double immunofluorescence staining results that they re-expressed epithelial markers CK7 and E-cadherin, rather than mesenchymal markers αSMA and vimentin, suggested that these transitioning HPCs may not complete the EMT cascade and launch the reverse process MET to gain epithelial features. However, this study mainly focused on human pathological tissues. Further experiments, especially in vitro and animal model studies, are required to explore the exact role of regulatory cytokines and microenvironment.

Abbreviations

BM: Bone marrow; CK: Cytokeratin; DRs: Ductular reactions; EM: Electron microscopic; EMT/MET: Epithelial-mesenchymal transition/ mesenchymal-epithelial transition; FSP1: Fibroblast-specific protein 1; H&E: Hematoxylin and eosin; HGF: Hepatocyte growth factor; HPCs: Hepatic progenitor cells; IHLCs: Intermediate hepatocyte-like cells; LCM: Laser capture microdissection; MMPs: Matrix metalloproteinases; OSM: Oncostatin M; RAGE: Advanced glycation endproducts; RT-qPCR: Quantitative reverse transcription PCR; αSMA: α-smooth muscle actin

Acknowledgements

None.

Funding

This study was supported by a grant from the National Natural Science Foundation of China (No. 81300347, 30571823, 81000174), the Natural Science Foundation of Jiangxi Province, China (No. 20132BAB205037, 20151BBG2000, 20151BAB215008, 20114BAB205016), Foundation of Jiangxi Educational Department (No. GJJ14192 and Foundation of Health and Family Planning Commission of Jiangxi Province (No. 201555992, 201555103, 20161086).

Availability of data and materials

We declared that materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes, without breaching participant confidentiality.

Authors’ contributions

XW, WNN, WHF, FQ and DJ carried out the immunohistochemical studies and drafted the manuscript. GZQ, SJ, LXL and YXF carried out the histological studies. ZL, HJP, HXF, QXQ and DYJ collected clinical data and participated in the histology analysis. GR and GY participated in the design of the study and performed the statistical analysis. WMM participated in the EM analysis. XJC and DH conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Authors’ information

None.

Competing interests

The author(s) declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The authors declare that this study was approved by the Ethics Committee of Ruijin Hospital and The Fourth Affiliated Hospital of Nanchang University (No. RJR2014-01236 and No. SFYNCU2014-0005, respectively).

Author details

1Department of General Surgery, Jiangxi Children’s Hospital, Nanchang, China. 2Molecular Medicine and Genetics Center, The Fourth Affiliated Hospital of Nanchang University, Nanchang, China. 3Department of Gastroenterology, The Fourth Affiliated Hospital of Nanchang University, Nanchang, China. 4Department of Pathology, Ruijin Hospital, School of
41. Valdes F, Alvarez AM, Locascio A, Vega S, Herrera B, Fernandez M, et al. The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. Mol Cancer Res. 2002;1(1):68–78.

42. Yimlamai D, Christodoulou C, Galli GG, Yang K, Pepe-Mooney B, Gurung B, et al. Hippo pathway activity influences liver cell fate. Cell. 2014;157(6):1324–38. doi:10.1016/j.cell.2014.03.060.

43. Anzai K, Chikada H, Tsuruya K, Ida K, Kagawa T, Inagaki Y, et al. Foetal hepatic progenitor cells assume a cholangiocyte cell phenotype during two-dimensional pre-culture. Sci Rep. 2016;6:28283. doi:10.1038/srep28283.

44. Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, et al. TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012;22(3):291–303. doi:10.1016/j.ccr.2012.07.023.

45. Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, et al. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest. 2008;88(2):112–23. doi:10.1038/labinvest.3700794.

46. Askenasy N, Kaminitz A, Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun Rev. 2008;7(5):370–5. doi:10.1016/j.autrev.2008.03.001.

47. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med. 2013;19(7):859–68. doi:10.1038/nm.3251.

48. Cepek KL, Shaw SK, Parker CM, Russell GJ, Morrow JS, Rimm DL, et al. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. Nature. 1994;372(6502):190–3. doi:10.1038/372190a0.

49. Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140(6):871–82. doi:10.1016/j.cell.2010.02.029.

50. Pusterla T, Nemeth J, Stein I, Wlechert L, Knigin D, Marhenke S, et al. Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice. Hepatology. 2013;58(1):363–73. doi:10.1002/hep.26195.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit